Zimmer Biomet Holdings, Inc.
General ticker "ZBH" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $20.2B (TTM average)
Zimmer Biomet Holdings, Inc. does not follow the US Stock Market performance with the rate: -5.4%.
Estimated limits based on current volatility of 1.6%: low 92.79$, high 95.78$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-09-30, amount 0.24$ (Y1.03%)
- Total employees count: 17000 (-5.6%) as of 2024
- US accounted for 57.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Supply chain disruptions, Cybersecurity threats, Regulatory and compliance, ERP system transition
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [82.67$, 124.15$]
- 2025-12-31 to 2026-12-31 estimated range: [85.67$, 128.30$]
Financial Metrics affecting the ZBH estimates:
- Negative: with PPE of 13.3 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 16.74
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 6.94
- Positive: 41.86 < Shareholder equity ratio, % of 58.36 <= 63.39
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 4.06
- Positive: -4.48 < Investing cash flow per share per price, % of -4.11
- Positive: Industry inventory ratio change (median), % of -1.44 <= -0.15
Short-term ZBH quotes
Long-term ZBH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $6,939.90MM | $7,394.20MM | $7,678.60MM |
| Operating Expenses | $6,243.60MM | $6,116.50MM | $6,392.90MM |
| Operating Income | $696.30MM | $1,277.70MM | $1,285.70MM |
| Non-Operating Income | $-292.80MM | $-210.40MM | $-249.10MM |
| Interest Expense | $164.80MM | $201.20MM | $218.00MM |
| R&D Expense | $406.00MM | $458.70MM | $437.40MM |
| Income(Loss) | $403.50MM | $1,067.30MM | $1,036.60MM |
| Taxes | $112.30MM | $42.20MM | $131.40MM |
| Other Income(Loss) | $-58.80MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $231.40MM | $1,024.00MM | $903.80MM |
| Stockholders Equity | $12,020.30MM | $12,480.50MM | $12,468.10MM |
| Inventory | $2,147.20MM | $2,385.20MM | $2,235.30MM |
| Assets | $21,066.00MM | $21,496.90MM | $21,365.30MM |
| Operating Cash Flow | $1,284.70MM | $1,581.60MM | $1,499.40MM |
| Capital expenditure | $217.60MM | $394.50MM | $356.80MM |
| Investing Cash Flow | $-529.20MM | $-778.90MM | $-888.10MM |
| Financing Cash Flow | $-843.80MM | $-763.50MM | $-484.50MM |
| Earnings Per Share** | $1.10 | $4.91 | $4.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.